December 21, 2004

Ambry Genetics Awarded College of American Pathologists Accreditation
Now part of an exclusive group of more than 6,000 laboratories worldwide that have met the highest standards of excellence

IRVINE, CA (December 21, 2004) – AMBRY GENETICS, a leading genetic testing company, announced it has met all applicable standards and is fully accredited by the College of American Pathologists (CAP) laboratory accreditation program based on results of a recent on-site inspection. The College is the world's largest association composed exclusively of pathologists and is widely considered the leader in laboratory quality assurance.

“Achieving CAP accreditation is another milestone in advancing our corporate goals,” said Charles Dunlop, Chief Executive Officer of Ambry Genetics. “This accrediatation opens new opportunities for us to expand our business and further establishes our quality reputation and leadership position in the fast-paced genomics marketplace,” continued Dunlop.

During the CAP accreditation process, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine the entire staff’s qualifications, the laboratory’s equipment, facilities, safety program and record, as well as the overall management of the laboratory. The CAP Laboratory Accreditation Program, begun in the early 1960s, is recognized by the federal government as being equal to or more stringent than the government’s own inspection program. This stringent inspection program is designed to specifically ensure the highest standard of care for the laboratory’s customers.

AMBRY GENETICS

Ambry Genetics is a worldwide leader in specialized genetic testing. The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns. Capable of identifying more than 99% of the known disease-causing mutations of the CFTR gene, the company’s reputable Cystic Fibrosis test has an unrivaled detection rate of over 96% across all ethnic groups. The Company also created the world’s first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics most recent development detects mutations of the most significant genes (MLH1, MSH2) causing hereditary colon cancer, significantly optimizing patient management and risk assessment. Headquartered in Irvine, California, the Company’s advancements are providing precise, cost effective methods to aid in disease definition and early, more accurate diagnosis. Several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes. Ambry Genetics is a CAP accredited laboratory. Website: www.ambrygen.com.

# # #